Dalton Medicinal Chemistry Partners is utilizing its medicinal chemistry expertise to design and synthesize novel compounds against an antiviral target selected by Boehringer Ingelheim (Canada).
Peter Pekos, president of Dalton Pharma Services, said: “We are pleased to achieve this milestone in our exciting partnership with Boehringer Ingelheim (Canada) Ltd. It is a pleasure working with the talented team at Boehringer Ingelheim.”